TY - JOUR AU - Xia, Liang AU - Zhu, Yunke AU - Zhang, Chuanfen AU - Deng, Senyi AU - Deng, Yulan AU - Yang, Zhenyu AU - Mei, Jiandong AU - Liu, Lunxu PY - 2019 TI - Decreased expression of EFCC1 and its prognostic value in lung adenocarcinoma JF - Annals of Translational Medicine; Vol 7, No 22 (November 29, 2019): Annals of Translational Medicine Y2 - 2019 KW - N2 - Background: So far, there is a lack of reliable prognostic biomarkers for lung adenocarcinoma (ADC). Initially, we found that EF-hand and coiled-coil domain containing 1 (EFCC1) was a novel gene which was downregulated consistently with the progression of lung ADC in The Cancer Genome Atlas (TCGA) data through bioinformatics analysis. In this study, we aimed to evaluate the prognostic significance of EFCC1 in lung ADC in both TCGA data and clinical samples. Methods: Firstly, the expression level and prognostic significance of EFCC1 in lung ADC were investigated in TCGA data. Then, the expression level of EFCC1 was validated by qPCR, Western blot, and immunohistochemistry (IHC) in five clinical lung ADC and matched adjacent non-tumor tissues. Finally, the association of EFCC1 expression with clinicopathological characteristics and overall survival (OS) in lung ADC patients was further evaluated in 130 clinical lung ADC samples with tissue microarray (TMA). Results: In TCGA data, we found that decreased mRNA expression (P Conclusions: Our findings suggested that decreased expression of EFCC1 was significantly associated with progression of lung ADC and could serve as a novel prognostic biomarker for lung ADC patients. UR - https://atm.amegroups.org/article/view/31484